PE20151543A1 - Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso - Google Patents

Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso

Info

Publication number
PE20151543A1
PE20151543A1 PE2015001930A PE2015001930A PE20151543A1 PE 20151543 A1 PE20151543 A1 PE 20151543A1 PE 2015001930 A PE2015001930 A PE 2015001930A PE 2015001930 A PE2015001930 A PE 2015001930A PE 20151543 A1 PE20151543 A1 PE 20151543A1
Authority
PE
Peru
Prior art keywords
oral pharmaceutical
methods
pharmaceutical composition
tablets
sulphate salts
Prior art date
Application number
PE2015001930A
Other languages
English (en)
Inventor
Jr Edmund V Dennett
David S Wells
Original Assignee
Braintree Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintree Lab filed Critical Braintree Lab
Publication of PE20151543A1 publication Critical patent/PE20151543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion para un comprimido farmaceutico oral que comprende una sal de sulfato, por ejemplo, sulfato de sodio, en donde la composicion se puede administrar por ingestion oral directa y por desintegracion en agua antes de la ingesta oral. Uso de dichas formulaciones para un comprimido farmaceutico oral para inducir la laxacion o para tratar o prevenir la constipacion
PE2015001930A 2013-03-15 2014-03-14 Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso PE20151543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798759P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151543A1 true PE20151543A1 (es) 2015-11-29

Family

ID=50680164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001930A PE20151543A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso

Country Status (24)

Country Link
US (2) US9919007B2 (es)
EP (2) EP2968174B1 (es)
JP (2) JP6441890B2 (es)
CN (2) CN105142617B (es)
AU (3) AU2014227598B2 (es)
BR (1) BR112015019776A2 (es)
CA (1) CA2903283C (es)
CY (1) CY1122387T1 (es)
DK (1) DK2968174T3 (es)
EA (2) EA034234B1 (es)
ES (1) ES2764462T3 (es)
HK (1) HK1214519A1 (es)
HR (1) HRP20192227T1 (es)
HU (1) HUE046754T2 (es)
IL (1) IL241367A0 (es)
LT (1) LT2968174T (es)
ME (1) ME03656B (es)
MX (1) MX2015012109A (es)
PE (1) PE20151543A1 (es)
PL (1) PL2968174T3 (es)
PT (1) PT2968174T (es)
RS (1) RS59667B1 (es)
SI (1) SI2968174T1 (es)
WO (1) WO2014144407A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59667B1 (sr) 2013-03-15 2020-01-31 Braintree Laboratories Inc Oralna farmaceutska kompozicija sulfatnih soli u obliku tableta dvostruke primene i postupci njihove upotrebe
EP3191105A4 (en) * 2014-09-12 2018-05-02 Braintree Laboratories, Inc. Sulfate salt solution laxative compositions and methods of use thereof
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
EP4232008A1 (en) * 2020-10-26 2023-08-30 Braintree Laboratories, Inc. Sulfate salt formulations for colon cleansing

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873694A (en) 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
JPS5438167B2 (es) 1974-04-27 1979-11-19
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2058565B (en) 1979-09-21 1983-12-07 Leo Pharm Prod Ltd Layer tablets
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3134591A1 (de) 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPS5839618A (ja) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
DE3266580D1 (en) 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59101423A (ja) 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
JPS6097919A (ja) 1983-11-01 1985-05-31 Furointo Sangyo Kk 圧縮成形用賦形剤の製造方法
NL8400911A (nl) 1984-03-22 1985-10-16 Dagra Nv Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
EP0231356A1 (en) 1985-08-01 1987-08-12 Braintree Laboratories, Inc. Low-sodium laxative and lavage formulation
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
NO168563C (no) 1987-09-28 1992-03-11 Collett Marwell Hauge As Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv
JPH0194937A (ja) * 1987-10-06 1989-04-13 Yokohama Yushi Kogyo Kk 微粉状ミネラル類の被覆物の製造方法
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
WO1989005659A1 (en) 1987-12-24 1989-06-29 Borody Thomas J Orthostatic lavage solutions
WO1989009604A1 (en) 1988-04-05 1989-10-19 Dale Driver Dietary mineral sulfur supplement
JPH0816061B2 (ja) 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
IT1229568B (it) 1989-04-17 1991-09-04 Giuliani Spa Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
CZ218394A3 (en) 1992-03-11 1995-01-18 Procter & Gamble Plantain drinking mixtures containing granulated base
JPH08505609A (ja) 1992-11-24 1996-06-18 ブロック・ドラッグ・カンパニー・インク 胃腸洗浄用薬剤組成物
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5498425A (en) 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
DE69627170T2 (de) 1996-05-08 2004-03-04 Aronchick, Graig A. Nichtwässrige abführmittel für den kolon
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
ES2202855T3 (es) 1997-04-18 2004-04-01 Janssen Pharmaceutica Nv Uso de antagonistas 5ht3 para promover el lavado intestinal.
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
CA2348024C (en) 1998-10-30 2008-02-19 Mcneil-Ppc, Inc. Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof
US6645481B1 (en) 2000-09-28 2003-11-11 Braintree Laboratories, Inc. Method of achieving overnight laxation and control of bowel function
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
AUPR590701A0 (en) 2001-06-25 2001-07-19 Colocaps Pty Ltd Laxative preparation
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
US20040071779A1 (en) 2002-10-09 2004-04-15 Keiser Dale Arthur Gelled laxative compositions
US7291324B2 (en) 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
EP1663257B1 (en) 2003-07-09 2009-01-07 Braintree Laboratories, Inc. Use of laxatives for treating irritable bowel syndrome
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
GB0409104D0 (en) 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
PT1750702E (pt) 2004-06-04 2010-11-11 Braintree Lab Método de lavagem intestinal
WO2007013093A2 (en) 2005-04-01 2007-02-01 Shiv Prakash Laxative formulation containing a triphala extract
WO2006118562A1 (en) 2005-04-29 2006-11-09 Inkine Pharmaceutical Company, Inc. Purgative composition and uses thereof
AU2006244112B2 (en) 2005-05-06 2011-02-17 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
US20070087056A1 (en) 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070082061A1 (en) 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
JP2009521994A (ja) 2005-12-29 2009-06-11 ブレーントリー ラボラトリーズ インコーポレーティッド 仮想結腸内視鏡検査を目的として結腸を準備するための、浸透圧性緩下薬および刺激性緩下薬を含むキット
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
NZ580999A (en) 2007-05-17 2012-05-25 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
EP2211838A2 (en) 2007-10-17 2010-08-04 Thomas Jefferson University Bowel purgative and uses thereof
JP2011510020A (ja) 2008-01-16 2011-03-31 ブレーントリー ラボラトリーズ インコーポレーティッド 硫酸塩による予防法および治療法
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
DK2294012T3 (da) 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
US20100255122A1 (en) 2009-04-02 2010-10-07 Garren Mary L Edible gelatin bowel preparation and bowel cleansing method
JP5759450B2 (ja) 2009-04-21 2015-08-05 バックウィッチ, デール, アール.BACHWICH, Dale, R. 大腸洗浄システム
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
GB0912487D0 (en) 2009-07-17 2009-08-26 Norgine Bv Improvements in and relating to colon cleansing compositions
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
BR112012022775A2 (pt) 2010-03-10 2016-07-19 Nogra Pharma Ltd composições para a lavagem, do cólon e métodos para a produção e utilização das mesmas
EP2544543A1 (en) 2010-03-12 2013-01-16 Scott Cordray Method of treatment
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
EP2598123A1 (en) 2010-07-27 2013-06-05 Norgine BV Compositions
JP5872573B2 (ja) 2010-11-04 2016-03-01 ノージン ビーブイ ポリエチレングリコール含有製剤
JP6121334B2 (ja) 2010-12-13 2017-04-26 サリックス ファーマシューティカルズ，インコーポレイテッド 胃および結腸製剤ならびにそれらを作製するための方法および使用するための方法
JP5876418B2 (ja) * 2010-12-28 2016-03-02 大鵬薬品工業株式会社 口腔内崩壊錠剤
CN105963701A (zh) 2011-01-28 2016-09-28 布伦特里实验室有限公司 用于肠道清洁的方法、组合物以及包装
CN103458874A (zh) 2011-01-31 2013-12-18 诺金股份有限公司 对组合物的改进和与组合物有关的改进
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
ES2652490T3 (es) 2011-04-15 2018-02-02 Braintree Laboratories, Inc. Sales de sulfato como potenciador del tiempo de tránsito
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
US20140235730A1 (en) 2011-09-23 2014-08-21 Gavis Pharmaceuticals, Llc Solid, edible, chewable laxative composition
CA2853520C (en) 2011-10-27 2021-11-16 Thomas Julius Borody Electrolyte purgatives
US9149493B2 (en) 2011-11-28 2015-10-06 Alfa Wassermann Spa Compositions for bowel cleansing and use thereof
CA2882316A1 (en) 2012-08-29 2014-03-06 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
KR102257207B1 (ko) 2012-09-11 2021-05-31 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
US20140087007A1 (en) 2012-09-27 2014-03-27 Braintree Laboratories, Inc. Bowel cleansing preparations
RS59667B1 (sr) 2013-03-15 2020-01-31 Braintree Laboratories Inc Oralna farmaceutska kompozicija sulfatnih soli u obliku tableta dvostruke primene i postupci njihove upotrebe

Also Published As

Publication number Publication date
AU2014227598A1 (en) 2015-08-27
EP3563838A1 (en) 2019-11-06
CN105142617B (zh) 2018-08-03
ME03656B (me) 2020-07-20
BR112015019776A2 (pt) 2017-07-18
EA201591568A1 (ru) 2015-12-30
CN108904462A (zh) 2018-11-30
PT2968174T (pt) 2020-01-15
AU2020213378A1 (en) 2020-08-27
EA201992382A2 (ru) 2020-02-28
SI2968174T1 (sl) 2020-02-28
CA2903283A1 (en) 2014-09-18
JP2016514677A (ja) 2016-05-23
EA201992382A3 (ru) 2020-05-31
JP2019023244A (ja) 2019-02-14
PL2968174T3 (pl) 2020-05-18
HUE046754T2 (hu) 2020-03-30
RS59667B1 (sr) 2020-01-31
IL241367A0 (en) 2015-11-30
EP2968174A1 (en) 2016-01-20
DK2968174T3 (da) 2019-12-16
CA2903283C (en) 2023-09-05
CN105142617A (zh) 2015-12-09
WO2014144407A8 (en) 2014-11-20
US20180207200A1 (en) 2018-07-26
US9919007B2 (en) 2018-03-20
LT2968174T (lt) 2020-01-10
JP6441890B2 (ja) 2018-12-19
JP6724114B2 (ja) 2020-07-15
MX2015012109A (es) 2016-04-15
EP2968174B1 (en) 2019-10-16
HRP20192227T1 (hr) 2020-02-21
EA034234B1 (ru) 2020-01-20
ES2764462T3 (es) 2020-06-03
AU2014227598B2 (en) 2018-12-06
HK1214519A1 (zh) 2016-07-29
AU2019201511A1 (en) 2019-03-28
WO2014144407A1 (en) 2014-09-18
CY1122387T1 (el) 2020-11-25
US20160030473A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
GT201400069A (es) Composiciones farmaceuticas
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
CL2012002437A1 (es) Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EA201590732A1 (ru) Диспергируемая таблетка
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido